Member Info for Hurst10

Plug Power Announces Execution of Definitive Agreement to Acquire Applied Cryo Technologies

Since NY 07.00 AM barely any selling and we are moving higher.

With all the positive press comments from IATA etc, NY will pick it up and we will have the usual US buyer picking up stock.

U.K.’s Johnson Slammed by MPs for ‘Fatalistic Approach’ to Covid
https://www.bloomberg.com/news/articles/2021-10-11/u-k-s-johnson-slammed-by-mps-for-fatalistic-approach-to-covid

https://t.co/SzdEG7HsUR

New variant not being picked up by the PCR tests

This will be discussed at the Quidel”s opening :
Quidel is looking to further improve its EBITDA margins to 35% through M&A. While there are no current deals in the pipeline, Quidel's past track record in M&A is a promising indicator. It is expected for Quidel to potentially realize its goals in the next few years giving it a further edge against its competitors. Based on company statements, they are aiming to "pursue strategic M&A". Their presentation also highlights one of their key expansion strategies via M&A. Based on this, we believe that they are highly likely to carry out M&A deals in the near future.
A potential deal between Quidel and QIAGEN (QGEN) fell through in February 2021. However, this deal provides us with insights into the potential targets that Quidel is looking for. QIAGEN, which is a competitor of Quidel, specializes in a range of diagnostics products that enables its POC testing kits in food testing, veterinary care, forensic tests, environment tests, and lifestyles. They also provide products that can be purchased directly for home use which is still an untapped market for Quidel. A merger with a company like QIAGEN will certainly open up new markets to Quidel as they currently only focus on diagnostics testing devices. Entering new markets could fuel Quidel's expansion rapidly and gain a larger market share in the future.

As expected :
“ leaders and health officials fear there is a realistic possibility 60,000 people could die from flu this winter, as the government renewed calls for people to get vaccinated against the influenza virus as soon as possible.
Cases of coronavirus, flu and other respiratory infections are likely to surge in the months ahead, experts say, culminating in increased hospitalisations and rising pressure on health services across England.”

Nice post US hours announcement:
Quidel rallies on Q3 prelim revenue seen significantly higher then analysts estimates https://seekingalpha.com/news/3750781-quidel-rallies-on-q3-prelim-revenue-seen-significantly-higher-then-analysts-estimates?source=copyToPasteboard

Meanwhile in the US:
https://www.reuters.com/business/healthcare-pharmaceuticals/rapid-covid-19-tests-increasingly-scarce-pricey-demand-employers-jumps-2021-10-05/

The White House will invest another $1B to boost supplies of COVID-19 at-home tests, CNN reports.
As a result, the number of rapid at-home tests that will be available to Americans will quadruple by December, Bloomberg reports.
A decline in COVID-19 cases earlier this year led to test manufacturers cutting back supply, only to lead to a shortage as a result of the delta variant and employer testing mandates.

80% buyers today so far

Pfizer/BioNTech's COVID-19 vaccine efficacy wanes after 6 months: Study

He was very confident and ?pleased? with the AVA6000 trials, stand by for more news

Bottom line is; coming into Q4 with LFT replacing PCR’s, there is simply not enough supply anywhere! In the US, Europe etc
Avacta will face once OTC approved a demand from Asia, Australia and Europe and off course Europe and the previous est monthly manufacturing capacity of 30 mill a month + more, will be taken up immediately by Governments etc. Daily, weekly use of LFT.
The shortage of LFT globally, will make the chip shortage look like a joke.
As mentioned before 150 before results and 260 the following week or two, then the market will have to go back to the drawing board and come up with a new target price!

Covid testing firms are facing a shortage of lateral flow tests, says Transport Secretary Grant Shapps.

Avacta going to have EUA by the FDA, need it .

President Joe Biden is betting on millions more rapid, at-home tests to help curb the latest deadly wave of the COVID-19 pandemic, which is overloading hospitals and threatening to shutter classrooms around the country.

But the tests have already disappeared from pharmacy shelves in many parts of the U.S., and manufacturers warn it will take them weeks to ramp up production, after scaling it back amid plummeting demand over the summer.

The latest shortage is another painful reminder that the U.S. has yet to successfully manage its COVID-19 testing arsenal, let alone deploy it in the type of systematic way needed to quickly crush outbreaks in schools, workplaces and communities.

FDA Warns of Potential False Positives With Abbott SARS-CoV-2 Molecular Tests
The U.S. Food and Drug Administration (FDA) is alerting clinical laboratory staff and health care providers of a potential for false positive results with the Alinity m SARS-CoV-2 AMP Kit, List Number 09N78-095, and Alinity m Resp-4-Plex AMP Kit, List Number 09N79-096. The false positive results may be related to current mixing parameters of the PCR reaction mixture that may result in potential overflow that could carry over into neighboring wells in the assay reagent tray. Overflow into the wells of true negative samples that are positioned near positive samples in the assay tray could produce false positive results.

I doubt very much one can apply a trend line analysis or even any technical analysis to Avacta or most of biotech stocks, as they are driven by events and news only!
If one look at last year when they share price took off, which trend line was broken then?
The trouble you have with a stock like Avacta, is impatient investors, who always buy and sell at the wrong levels and blames everyone else, apart from themselves.
The key investors will and have taken advantage of days like that and to talk of a placing during a close period is very silly.
We will have fireworks on results day, with updates and guidance that most likely, will have the market scrambling to adjust their numbers upwards and the phrase used in previous notes “ upside risk to their estimates “ will very much feature.
So hold your nerve, pick up more at these levels and you will be sitting on + 50% by the 1st of October.
There is M&A, JV’s and IPO’s etc going on every day in the sector and if one were to apply the sort of valuation used, well then we have a company which is one the cheapest in the sector.
With the recent announcements of Triple A sector experts having joined the company, we have only commenced a period of very positive news flow.

Novartis acquiring another gene therapy company, this time
optogenetics-based AAV gene therapy program.
Both Roche and Novartis have been very active in the M&A in the Gene therapy area.

Once OTC approval have been secured, perhaps pre results, an order from the Military forces could be on the cards.
As seen with Quidel in the US.
U.K. forces buying U.K. testing!